WorldLab-EuroMedLab
Roma 2023
What to expect when you visit Siemens Healthineers in Rome
Pioneering breakthroughs in healthcare. For everyone. Everywhere.
We're looking forward to seeing you!
Visit our EuroMedLab home page to learn about the trends in clinical diagnostics that we're talking about this year.
Register for exclusive access to expert videos and insights and get personalized recommendations.
Tour our booth
Join Siemens Healthineers at WorldLab-EuroMedLab in Booth #18, Foyer Level -1 to see the latest innovations and meet our team of experts.
Special Events
The instrumental role of the clinical laboratory in identifying high-risk patients with NAFLD: A sequential algorithm to detect advanced liver fibrosis. Discussions will include:
Workshop WS11, La Nuvola, Floor 1, Room 1
24 May 2023 | 13.00 – 14.40
Agenda
Congress Dates: 21 – 25 May 2023
Exhibition: 22 – 24 May 2023, 09.00 - 17.30 daily
Sunday 21 May | Time | Location |
Congress Opening Ceremony and Welcome Reception | 17.00 – 20.00 | La Nuvola Auditorium |
Monday 22 May | ||
Trend Talk: | 11.30 | Live in the Siemens Healthineers booth or |
Poster Session and Lunch | 12.45 – 14.00 | La Nuvola Entrance Hall |
Trend Talk: | 15.00 | Live in the Siemens Healthineers booth or |
Tuesday 23 May | ||
Trend Talk: | 11.30 | Live in the Siemens Healthineers booth or |
Poster Session and Lunch | 12.45 – 14.00 | La Nuvola Entrance Hall |
Wednesday 24 May | ||
Trend Talk: | 11.30 | Live in the Siemens Healthineers booth or |
Poster Session and Lunch | 12.45 – 14.00 | La Nuvola Entrance Hall |
NAFLD Educational Workshop: The instrumental role of the clinical laboratory in identifying high-risk patients with NAFLD. Educational workshop hosted by Siemens Healthineers to discuss:
| 13.00 – 14.00 | Workshop WS11, Floor 1, Room 1 |
Scientific Posters
Posters will be displayed in electronic format on interactive totems located in the entrance hall of the congress venue and on the congress app.
Poster Title | Author(s) (Presenter in bold) |
N Latex FLC kappa and lambda Assays for Monitoring AL Amyloidosis: Comparison Study versus Clinical Assessment and FREELITE Assays | Gentzer W, Agis M, Palladini G, Willrich M |
Performance Evaluation of the Newly Developed N Latex ATNFA Reagent for Therapeutic Drug Monitoring (TDM) of the TNFα Inhibitors Adalimumab, Infliximab, and Etanercept Using Automated Siemens Healthineers Immunonephelometry Systems | Freidel C, Mueller L, Weisspflug E, Schelp C. |
Atellica CI 1900 Assay Sigma Metrics Evaluation | Kristopher Kolewe, Harry Leipold, Sandra Lewisch, Jason Snyder, Geoff Wilkins |
Performance Evaluation of the Atellica CI 1900 High-Sensitivity Troponin I Assay | Charbel Abou-Diwan, Hairong Zhang, Harry Leipold |
Evaluation of the Analytical Performance of BNP and NT-proBNP Assays on the Atellica CI 1900 Analyzer | Charbel Abou-Diwan, Nazira Ozgen, Harry Leipold |
Evaluation of the Analytical Performance of Thyroid-stimulating Hormone, Free Triiodothyronine, and Free Thyroxine Assays on the Atellica CI 1900 | Charbel Abou-Diwan, Mike Quintanilla, Hairong Zhang, Ming Guo, Harry Leipold |
Atellica CI 1900 Sample Carryover Performance Evaluation | Pham T, Kolewe K, Ho M, Lewisch S, Snyder J |
Atellica VTLi hs-cTnI shelf life, in-use stability and sample stability | Danielle Kemper, Bernadet Meijering, Trees van Domburg, Frank Wijnands, Nina van Rodenburg, Judy Fonville |
Venue Information
Join us at La Nuvola!
Booth #18, Foyer Level -1
2023 Roma Congress Information
Location: Rome, Italy
Venue: Centro Congressi Roma La Nuvola
(map)
Register for the show at 2023Roma.org.
Hosted by
Availability of products mentioned herein may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.
In the U.S. the ELF Test is not for use in the diagnosis of NASH or for the staging of fibrosis. The ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events.